# Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

> **NCT06609460** · PHASE2 · COMPLETED · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 5071 (actual)

## Conditions studied

- Influenza

## Interventions

- **COMBINATION_PRODUCT:** CD388 Injection
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT06609460
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-20
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-09-19
- **Target enrollment:** 5071 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609460, "Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06609460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*